IGHE and asthma: In this manuscript we report the effects of using mepolizumab in patients with CF and type 2 inflammation.<h4>Results</h4>We present three patients with CF (63, 34 and 24 year of age) and personal history of asthma, who displayed significant eosinophilic inflammation and high total serum IgE concentrations (type 2 inflammation) who were treated with mepolizumab.